<p>Avalo Therapeutics（纳斯达克股票代码：AVTX - 获取免费报告）在周四向投资者发布的一份报告中，投资分析师 Citizens Jmp 将其目标价格从 62.00 美元下调至 55.00 美元，Benzinga 报道。该公司目前对该股票的评级为 “市场表现优于大盘”。Citizens Jmp 的目标价格意味着该股票相较于之前的收盘价有 182.85% 的潜在上涨空间。</p>
<p>获取 <strong>Avalo Therapeutics</strong> 的提醒：</p>
<p>其他一些分析师最近也对 AVTX 发表了看法。华尔街 Zen 在 3 月 29 日的研究报告中将 Avalo Therapeutics 的股票评级从 “强烈卖出” 上调至 “持有”。Wolfe Research 在 4 月 9 日的报告中开始覆盖 Avalo Therapeutics，给予 “表现优于大盘” 的评级，并设定 48.00 美元的目标价格。Guggenheim 在 2 月 2 日的报告中开始覆盖 Avalo Therapeutics，给予 “买入” 评级，并设定 50.00 美元的目标价格。花旗集团在 5 月 6 日的研究报告中重申了 Avalo Therapeutics 的 “表现优于大盘” 评级。最后，HC Wainwright 在周四的研究报告中将 Avalo Therapeutics 的目标价格从 40.00 美元下调至 35.00 美元，并对该股票设定 “买入” 评级。共有 11 位分析师对该股票给予 “买入” 评级，1 位分析师给予 “卖出” 评级。根据 MarketBeat.com 的数据，Avalo Therapeutics 目前的共识评级为 “适度买入”，共识目标价格为 48.13 美元。</p>
<p><strong>阅读我们对 AVTX 的最新股票分析</strong></p>
<h2>Avalo Therapeutics 股价下跌 2.0%</h2>
<p>在周四的午盘交易中，AVTX 股票下跌 0.41 美元，报 19.45 美元。该股票的交易量为 195,228 股，而其平均交易量为 1,002,079 股。该公司的市值为 5.7032 亿美元，市盈率为-3.42，贝塔值为 0.78。Avalo Therapeutics 的 52 周低点为 3.43 美元，52 周高点为 24.27 美元。该股票的 50 日简单移动平均线为 15.84 美元，200 日简单移动平均线为 16.44 美元。</p>
<p>Avalo Therapeutics（纳斯达克股票代码：AVTX - 获取免费报告）最近在 5 月 13 日发布了季度财报。该公司报告每股收益为-0.98 美元，超出分析师的共识预期（-1.00 美元）0.02 美元。平均而言，股票分析师预测 Avalo Therapeutics 在当前年度的每股收益为-3.1。</p>
<h2>Avalo Therapeutics 的内部交易</h2>
<p>在其他新闻中，首席财务官 Christopher Ryan Sullivan 在 4 月 30 日的交易中出售了 8,457 股该股票。该股票的平均售价为 13.23 美元，总价值为 111,886.11 美元。交易完成后，首席财务官持有 423 股公司股票，价值 5,596.29 美元。这代表其持股比例减少了 95.24%。该交易已在向 SEC 提交的文件中披露，文件可通过此超链接获取。该交易是在预先安排的 10b5-1 交易计划下执行的。此外，内部人士 Paul Varki 在 5 月 6 日的交易中出售了 75,063 股该股票。该股票的平均售价为 20.17 美元，总价值为 1,514,020.71 美元。交易完成后，该内部人士直接持有 3,634 股公司股票，价值 73,297.78 美元。该交易使其持股比例减少了 95.38%。有关此次出售的更多细节可在官方 SEC 披露中找到。该交易是在预先安排的 10b5-1 交易计划下执行的。在过去 90 天内，内部人士共出售了 138,078 股公司股票，价值 2,501,346 美元。4.46% 的股票由内部人士持有。</p>
<h2>机构投资者对 Avalo Therapeutics 的看法</h2>
<p>大型投资者最近调整了对该公司的持股。Orbimed Advisors LLC 在第三季度将其在 Avalo Therapeutics 的持股增加了 39.5%。Orbimed Advisors LLC 目前拥有 1,349,300 股公司股票，价值 17,150,000 美元，此前在上个季度增持了 382,300 股。Nantahala Capital Management LLC 在第三季度将其在 Avalo Therapeutics 的持股增加了 24.1%。Nantahala Capital Management LLC 目前拥有 1,235,000 股公司股票，价值 15,697,000 美元，此前在上个季度增持了 240,000 股。Affinity Asset Advisors LLC 在第四季度将其在 Avalo Therapeutics 的持股增加了 4.5%。Affinity Asset Advisors LLC 目前拥有 1,051,054 股公司股票，价值 19,087,000 美元，此前在该期间增持了 44,837 股。Caligan Partners LP 在第四季度将其在 Avalo Therapeutics 的持股增加了 5.8%。Caligan Partners LP 目前拥有 881,533 股公司股票，价值 16,009,000 美元，此前在上个季度增持了 48,200 股。最后，Balyasny Asset Management L.P.在第三季度获得了 Avalo Therapeutics 的新股份，价值约 10,390,000 美元。目前 87.06% 的股票由机构投资者持有。</p>
<h2>Avalo Therapeutics 公司简介</h2>
<p>（获取免费报告）</p>
<p>Avalo Therapeutics 是一家临床阶段的生物技术公司，专注于心血管代谢、纤维化和炎症疾病的新疗法的发现、开发和商业化。该公司的专有药物设计平台能够创造具有优化药代动力学特征的长效前药，旨在提高疗效、安全性和患者依从性。通过利用这一技术，Avalo 旨在解决现有治疗方法未能满足的疾病进展的关键驱动因素。</p>
<p>其主要项目包括 AVTX-002，这是一种首创的前药候选药物，旨在抑制肾素原，用于治疗高血压及相关心血管疾病，以及 AVTX-006，这是一种早期候选药物，针对与纤维化和代谢功能障碍相关的途径。</p>
<h2>进一步阅读</h2>
<ul>
<li>我们更看好的五只股票，而不是 Avalo Therapeutics</li>
<li>Chime 最终实现盈利——但风险依然存在</li>
<li>eVTOL 投资：抛弃出租车，购买蓝图</li>
<li>伯克希尔对纽约时报的投资现状</li>
<li>Affirm 与谷歌的交易旨在影响你的钱包</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVZUWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVZUWA"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1,000 美元在 Avalo Therapeutics 吗？</h2>
<p>在考虑 Avalo Therapeutics 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已经识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Avalo Therapeutics 并不在名单上。</p>
<p>虽然 Avalo Therapeutics 目前在分析师中有中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

AVTX

纳斯达克生物科技指数 ETF - iShares Nasdaq

基因改革 ETF - ARK

<p>Citizens Jmp 已将 Avalo Therapeutics (NASDAQ:AVTX) 的目标股价从 62.00 美元下调至 55.00 美元，维持 “市场表现优于大盘” 的评级。这个新目标暗示该股票相较于之前的收盘价有 182.85% 的潜在上涨空间。其他分析师也给出了混合评级，普遍评级为 “适度买入”，目标股价为 48.13 美元。Avalo 的股票目前下跌 2.0%，报 19.45 美元，市值为 5.7032 亿美元。近期内部交易显示高管们进行了大量的股票出售</p>

<p>Avalo Therapeutics (NASDAQ:AVTX - Get Free Report) had its price objective decreased by investment analysts at Citizens Jmp from $62.00 to $55.00 in a note issued to investors on Thursday,Benzinga reports. The firm currently has a &#34;market outperform&#34; rating on the stock. Citizens Jmp's target price points to a potential upside of 182.85% from the stock's previous close.</p>
<div class="lb-trans"><p>Avalo Therapeutics（纳斯达克股票代码：AVTX - 获取免费报告）在周四向投资者发布的一份报告中，投资分析师 Citizens Jmp 将其目标价格从 62.00 美元下调至 55.00 美元，Benzinga 报道。该公司目前对该股票的评级为 “市场表现优于大盘”。Citizens Jmp 的目标价格意味着该股票相较于之前的收盘价有 182.85% 的潜在上涨空间。</p>
</div><p>Get <strong>Avalo Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Avalo Therapeutics</strong> 的提醒：</p>
</div><p>A number of other analysts have also recently weighed in on AVTX. Wall Street Zen raised shares of Avalo Therapeutics from a &#34;strong sell&#34; rating to a &#34;hold&#34; rating in a research note on Sunday, March 29th. Wolfe Research began coverage on Avalo Therapeutics in a report on Thursday, April 9th. They set an &#34;outperform&#34; rating and a $48.00 price objective on the stock. Guggenheim initiated coverage on Avalo Therapeutics in a report on Monday, February 2nd. They issued a &#34;buy&#34; rating and a $50.00 target price for the company. Citigroup restated an &#34;outperform&#34; rating on shares of Avalo Therapeutics in a research report on Wednesday, May 6th. Finally, HC Wainwright lowered their price target on Avalo Therapeutics from $40.00 to $35.00 and set a &#34;buy&#34; rating on the stock in a research report on Thursday. Eleven analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Avalo Therapeutics currently has a consensus rating of &#34;Moderate Buy&#34; and a consensus price target of $48.13.</p>
<div class="lb-trans"><p>其他一些分析师最近也对 AVTX 发表了看法。华尔街 Zen 在 3 月 29 日的研究报告中将 Avalo Therapeutics 的股票评级从 “强烈卖出” 上调至 “持有”。Wolfe Research 在 4 月 9 日的报告中开始覆盖 Avalo Therapeutics，给予 “表现优于大盘” 的评级，并设定 48.00 美元的目标价格。Guggenheim 在 2 月 2 日的报告中开始覆盖 Avalo Therapeutics，给予 “买入” 评级，并设定 50.00 美元的目标价格。花旗集团在 5 月 6 日的研究报告中重申了 Avalo Therapeutics 的 “表现优于大盘” 评级。最后，HC Wainwright 在周四的研究报告中将 Avalo Therapeutics 的目标价格从 40.00 美元下调至 35.00 美元，并对该股票设定 “买入” 评级。共有 11 位分析师对该股票给予 “买入” 评级，1 位分析师给予 “卖出” 评级。根据 MarketBeat.com 的数据，Avalo Therapeutics 目前的共识评级为 “适度买入”，共识目标价格为 48.13 美元。</p>
</div><p><strong>Read Our Latest Stock Analysis on AVTX</strong></p>
<div class="lb-trans"><p><strong>阅读我们对 AVTX 的最新股票分析</strong></p>
</div><h2>Avalo Therapeutics Trading Down 2.0%</h2>
<div class="lb-trans"><h2>Avalo Therapeutics 股价下跌 2.0%</h2>
</div><p>AVTX stock traded down $0.41 during midday trading on Thursday, hitting $19.45. The stock had a trading volume of 195,228 shares, compared to its average volume of 1,002,079. The firm has a market capitalization of $570.32 million, a price-to-earnings ratio of -3.42 and a beta of 0.78. Avalo Therapeutics has a 52 week low of $3.43 and a 52 week high of $24.27. The stock has a 50-day simple moving average of $15.84 and a 200 day simple moving average of $16.44.</p>
<div class="lb-trans"><p>在周四的午盘交易中，AVTX 股票下跌 0.41 美元，报 19.45 美元。该股票的交易量为 195,228 股，而其平均交易量为 1,002,079 股。该公司的市值为 5.7032 亿美元，市盈率为-3.42，贝塔值为 0.78。Avalo Therapeutics 的 52 周低点为 3.43 美元，52 周高点为 24.27 美元。该股票的 50 日简单移动平均线为 15.84 美元，200 日简单移动平均线为 16.44 美元。</p>
</div><p>Avalo Therapeutics (NASDAQ:AVTX - Get Free Report) last posted its quarterly earnings results on Wednesday, May 13th. The company reported ($0.98) earnings per share for the quarter, topping analysts' consensus estimates of ($1.00) by $0.02. On average, equities analysts forecast that Avalo Therapeutics will post -3.1 EPS for the current year.</p>
<div class="lb-trans"><p>Avalo Therapeutics（纳斯达克股票代码：AVTX - 获取免费报告）最近在 5 月 13 日发布了季度财报。该公司报告每股收益为-0.98 美元，超出分析师的共识预期（-1.00 美元）0.02 美元。平均而言，股票分析师预测 Avalo Therapeutics 在当前年度的每股收益为-3.1。</p>
</div><h2>Insider Transactions at Avalo Therapeutics</h2>
<div class="lb-trans"><h2>Avalo Therapeutics 的内部交易</h2>
</div><p>In other news, CFO Christopher Ryan Sullivan sold 8,457 shares of the stock in a transaction on Thursday, April 30th. The stock was sold at an average price of $13.23, for a total value of $111,886.11. Following the transaction, the chief financial officer owned 423 shares of the company's stock, valued at $5,596.29. This represents a 95.24% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Paul Varki sold 75,063 shares of the stock in a transaction dated Wednesday, May 6th. The shares were sold at an average price of $20.17, for a total value of $1,514,020.71. Following the completion of the transaction, the insider directly owned 3,634 shares in the company, valued at $73,297.78. The trade was a 95.38% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 138,078 shares of company stock worth $2,501,346 over the last 90 days. 4.46% of the stock is owned by insiders.</p>
<div class="lb-trans"><p>在其他新闻中，首席财务官 Christopher Ryan Sullivan 在 4 月 30 日的交易中出售了 8,457 股该股票。该股票的平均售价为 13.23 美元，总价值为 111,886.11 美元。交易完成后，首席财务官持有 423 股公司股票，价值 5,596.29 美元。这代表其持股比例减少了 95.24%。该交易已在向 SEC 提交的文件中披露，文件可通过此超链接获取。该交易是在预先安排的 10b5-1 交易计划下执行的。此外，内部人士 Paul Varki 在 5 月 6 日的交易中出售了 75,063 股该股票。该股票的平均售价为 20.17 美元，总价值为 1,514,020.71 美元。交易完成后，该内部人士直接持有 3,634 股公司股票，价值 73,297.78 美元。该交易使其持股比例减少了 95.38%。有关此次出售的更多细节可在官方 SEC 披露中找到。该交易是在预先安排的 10b5-1 交易计划下执行的。在过去 90 天内，内部人士共出售了 138,078 股公司股票，价值 2,501,346 美元。4.46% 的股票由内部人士持有。</p>
</div><h2>Institutional Investors Weigh In On Avalo Therapeutics</h2>
<div class="lb-trans"><h2>机构投资者对 Avalo Therapeutics 的看法</h2>
</div><p>Large investors have recently modified their holdings of the business. Orbimed Advisors LLC increased its position in shares of Avalo Therapeutics by 39.5% during the third quarter. Orbimed Advisors LLC now owns 1,349,300 shares of the company's stock worth $17,150,000 after acquiring an additional 382,300 shares in the last quarter. Nantahala Capital Management LLC lifted its position in Avalo Therapeutics by 24.1% in the 3rd quarter. Nantahala Capital Management LLC now owns 1,235,000 shares of the company's stock valued at $15,697,000 after acquiring an additional 240,000 shares in the last quarter. Affinity Asset Advisors LLC boosted its stake in Avalo Therapeutics by 4.5% in the 4th quarter. Affinity Asset Advisors LLC now owns 1,051,054 shares of the company's stock worth $19,087,000 after purchasing an additional 44,837 shares during the period. Caligan Partners LP increased its holdings in Avalo Therapeutics by 5.8% during the 4th quarter. Caligan Partners LP now owns 881,533 shares of the company's stock worth $16,009,000 after purchasing an additional 48,200 shares in the last quarter. Finally, Balyasny Asset Management L.P. acquired a new stake in Avalo Therapeutics in the 3rd quarter valued at approximately $10,390,000. 87.06% of the stock is currently owned by institutional investors.</p>
<div class="lb-trans"><p>大型投资者最近调整了对该公司的持股。Orbimed Advisors LLC 在第三季度将其在 Avalo Therapeutics 的持股增加了 39.5%。Orbimed Advisors LLC 目前拥有 1,349,300 股公司股票，价值 17,150,000 美元，此前在上个季度增持了 382,300 股。Nantahala Capital Management LLC 在第三季度将其在 Avalo Therapeutics 的持股增加了 24.1%。Nantahala Capital Management LLC 目前拥有 1,235,000 股公司股票，价值 15,697,000 美元，此前在上个季度增持了 240,000 股。Affinity Asset Advisors LLC 在第四季度将其在 Avalo Therapeutics 的持股增加了 4.5%。Affinity Asset Advisors LLC 目前拥有 1,051,054 股公司股票，价值 19,087,000 美元，此前在该期间增持了 44,837 股。Caligan Partners LP 在第四季度将其在 Avalo Therapeutics 的持股增加了 5.8%。Caligan Partners LP 目前拥有 881,533 股公司股票，价值 16,009,000 美元，此前在上个季度增持了 48,200 股。最后，Balyasny Asset Management L.P.在第三季度获得了 Avalo Therapeutics 的新股份，价值约 10,390,000 美元。目前 87.06% 的股票由机构投资者持有。</p>
</div><h2>Avalo Therapeutics Company Profile</h2>
<div class="lb-trans"><h2>Avalo Therapeutics 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Avalo Therapeutics is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for cardiometabolic, fibrotic and inflammatory diseases. The company's proprietary drug-design platform enables the creation of long-acting prodrugs with optimized pharmacokinetic profiles, aiming to improve efficacy, safety and patient adherence. By leveraging this technology, Avalo seeks to address key drivers of disease progression that remain underserved by existing treatments.</p>
<div class="lb-trans"><p>Avalo Therapeutics 是一家临床阶段的生物技术公司，专注于心血管代谢、纤维化和炎症疾病的新疗法的发现、开发和商业化。该公司的专有药物设计平台能够创造具有优化药代动力学特征的长效前药，旨在提高疗效、安全性和患者依从性。通过利用这一技术，Avalo 旨在解决现有治疗方法未能满足的疾病进展的关键驱动因素。</p>
</div><p>Its lead programs include AVTX-002, a first-in-class prodrug candidate designed to inhibit angiotensinogen for the treatment of hypertension and related cardiovascular disorders, and AVTX-006, an early-stage candidate targeting pathways implicated in fibrosis and metabolic dysfunction.</p>
<div class="lb-trans"><p>其主要项目包括 AVTX-002，这是一种首创的前药候选药物，旨在抑制肾素原，用于治疗高血压及相关心血管疾病，以及 AVTX-006，这是一种早期候选药物，针对与纤维化和代谢功能障碍相关的途径。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>进一步阅读</h2>
</div><ul>
<li>Five stocks we like better than Avalo Therapeutics</li>
<li>Chime Finally Turns Profitable—But Risks Remain</li>
<li>eVTOL Investing: Ditch the Taxi, Buy the Blueprint</li>
<li>How Berkshire’s New York Times Bet Looks Today</li>
<li>Affirm's Google Deal Aims for Your Wallet</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，而不是 Avalo Therapeutics</li>
<li>Chime 最终实现盈利——但风险依然存在</li>
<li>eVTOL 投资：抛弃出租车，购买蓝图</li>
<li>伯克希尔对纽约时报的投资现状</li>
<li>Affirm 与谷歌的交易旨在影响你的钱包</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVZUWA" alt="" original-src="https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx?Prefix=NASDAQ&amp;Symbol=AVTX"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Avalo Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Avalo Therapeutics 吗？</h2>
</div><p>Before you consider Avalo Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Avalo Therapeutics 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Avalo Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已经识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Avalo Therapeutics 并不在名单上。</p>
</div><p>While Avalo Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Avalo Therapeutics 目前在分析师中有中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Citizens Jmp Cuts Avalo Therapeutics (NASDAQ:AVTX) Price Target to $55.00

Market Beat

Avalo Therapeutics

Citizens Financial

花旗

CITIZENS FINANCIAL GROUP INC DEP SHS REPSTG 1/40TH PERP PFD SR I

CITIZENS FINANCIAL GROUP INC 5% DEP SHS EA REP 1/40TH NON CUM SER E

CITIZENS FINANCIAL GROUP INC DEP SHS REPSTG 1/40TH PERP PFD SER H

CITIGROUP INC 6.250 NON CUM SER II PFD WI

Citizens Jmp 将 Avalo Therapeutics（NASDAQ 代码：AVTX）的目标股价下调至 55.00 美元